Skip to main content
Fig. 2 | Molecular Cancer

Fig. 2

From: Plasma-derived exosomal miR-15a-5p as a promising diagnostic biomarker for early detection of endometrial carcinoma

Fig. 2

ddPCR validation of plasma exosmal miR-15a-5p, miR-106b-5p and miR-107 as diagnostic markers in 202 independent plasma samples. a The expression level of exosomal miR-15a-5p, miR-106b-5p, and miR-107 measured by ddPCR in independent validation samples. b ROC curves to validate the discrimination efficiency (for all EC with different stages vs HC) of exosomal miR-15a-5p, miR-106b-5p, miR-107, and their combinations (AUC = 0.832). n = 202. c ROC curves to validate the discrimination efficiency (for all EC with different stages vs HC) of exosomal miR-15a-5p, miR-106b-5p, miR-107, tumor biomarkers (TB), and their combinations (AUC = 0.885). CEA and CA125 were analyzed in TB analysis. n = 169. d ROC curves to validate the discrimination efficiency (for stage I EC vs HC) of exosomal miR-15a-5p, miR-106b-5p, miR-107, and their combinations (AUC = 0.815). Only EC patients with stage I in validation samples were analyzed for ROC curves. n = 170. e ROC curves to validate the discrimination efficiency (for stage I EC vs HC) of exosomal miR-15a-5p, miR-106b-5p, miR-107, TB (i.e., CEA and CA125), and their combinations (AUC = 0.875). n = 139. f The expression level of plasma-derived exosomal miRNAs from the same EC patients (n = 12) before and after surgery quantified by ddPCR. g-l The relationship between exosomal miR-15a-5p and clinical manifestations. Plasma-derived exosomal miR-15a-5p is differentially expressed between EC patients with p53 positive and negative staining (g), EC patients with depth of muscular infiltration < 1/2 and ≥ 1/2 (h), and EC patients with tumor size < 10 cm3 and ≥ 10 cm3 (i). Exosomal miR-15a-5p is positively correlated with TTE (j) and DHEAS (k), while is negatively correlated with E2 (l). TTE: testosterone; DHEAS: dehydroepiandrosterone sulfate; E2: estradiol

Back to article page